Abstract
Anti-PD-(L)1 agents play an important role in the management of NSCLC. PD-L1 analysis by immunohistochemistry is an important biomarker but displays temporospatial heterogeneity. In advanced NSCLC, metabolic parameters tumoural maximum standardised uptake value (SUVmax) and total lesion glycolysis (TLG) of 18F-FDG-PET/CT have been shown to correlate with PD-L1 expression. However, advanced status itself has been associated with high SUVmax and the relationship in early-stage disease has yet to be determined.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
